# InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO Steps Down, Eric So Named Interim Chief Executive Office

- URL: https://theranews.net/blog/2026-04-21-investornewsbreaks-helus-pharmatm-nasdaq-help-cboe-ca-help-ceo-steps-down-eric-s-6d87ba/
- Published: 2026-04-21
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: financialcontent
- Original report: https://www.financialcontent.com/article/nnwire-2026-4-20-investornewsbreaks-helus-pharmatm-nasdaq-help-cboe-ca-help-ceo-steps-down-eric-so-named-interim-chief-executive-office
- Topics: mental-health
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> This article has been disseminated on behalf of Helus Pharma and may include paid advertising.

---
Helus Pharma announced that Michael Cola has stepped down as Chief Executive Officer effective immediately at the request of the Board. Co-founder and Executive Chairman Eric So has been appointed as Interim CEO while the company conducts a search for a permanent successor.

The leadership transition is intended to ensure continuity as Helus Pharma advances its clinical pipeline, including the anticipated fourth-quarter topline data readout from the APPROACH trial of HLP003, while maintaining focus on long-term value creation for patients and shareholders. HLP003, a proprietary novel serotonergic agonist currently in Phase 3 development, has received FDA Breakthrough Therapy designation for adjunctive treatment of major depressive disorder.

Helus Pharma, the commercial operating name of Cybin Inc. (founded in 2019), is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists designed to activate serotonin pathways believed to promote neuroplasticity. Beyond HLP003, the company is also developing HLP004, a proprietary novel serotonergic agonist in Phase 2 for generalized anxiety disorder, and maintains an extensive research portfolio of investigational novel serotonergic agonists.

The company operates in Canada, the United States, the United Kingdom, and Ireland.

---

*This article is an AI-assisted summary. All facts and figures are drawn from the original report: [https://www.financialcontent.com/article/nnwire-2026-4-20-investornewsbreaks-helus-pharmatm-nasdaq-help-cboe-ca-help-ceo-steps-down-eric-so-named-interim-chief-executive-office](https://www.financialcontent.com/article/nnwire-2026-4-20-investornewsbreaks-helus-pharmatm-nasdaq-help-cboe-ca-help-ceo-steps-down-eric-so-named-interim-chief-executive-office)*